BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35865938)

  • 1. Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation.
    Zhang X; Zhao X; Shen Y; Shi Y; Zhang L; Hao M; Zhao F; Zhang R; Wei J; Feng S; He Y; Jiang E; Han M
    Front Pharmacol; 2022; 13():916472. PubMed ID: 35865938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation.
    Zhao Y; OuYang G; Shi J; Luo Y; Tan Y; Yu J; Fu H; Lai X; Liu L; Huang H
    Front Pharmacol; 2021; 12():668825. PubMed ID: 34262450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation.
    Bondeelle L; Chevret S; Hurabielle C; Samy L; Goletto T; Costantini A; Sicre de Fontbrune F; Michonneau D; Socié G; Tazi A; Bouaziz JD; Bergeron A
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2115-2120. PubMed ID: 32738501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
    Mohseni R; Mahdavi Sharif P; Behfar M; Modaresi MR; Shirzadi R; Mardani M; Jafari L; Jafari F; Nikfetrat Z; Hamidieh AA
    Stem Cell Res Ther; 2023 Sep; 14(1):256. PubMed ID: 37726865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
    Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
    Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
    Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
    JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical analysis of bronchiolitis obliterans syndrome after haplo- hematopoietic stem cell transplantation].
    Zhuang J; Gu B; Ke P; Liu YJ; Wu XJ; Xue SL; Hu XH; He XF; Ma X; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):404-410. PubMed ID: 31207706
    [No Abstract]   [Full Text] [Related]  

  • 9. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
    White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH
    Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical observation on the safety and efficacy of umbilical cord mesenchymal stem cells in the treatment of bronchiolitis obliterans after allogeneic haematopoietic stem cell transplantation.
    Li Z; Wang Y; Li G; Ma N; Li M; Yuan F; Fu Y; Wang L
    Biotechnol Genet Eng Rev; 2023 Mar; ():1-18. PubMed ID: 36856529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: A multicenter prospective cohort study.
    Chen S; Zhao K; Lin R; Wang S; Fan Z; Huang F; Chen X; Nie D; Du X; Guo Z; Lin D; Xuan L; Xu N; Sun J; Peng Xiang A; Liu Q
    EBioMedicine; 2019 Nov; 49():213-222. PubMed ID: 31668569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome.
    Kwok WC; Liang BM; Lui MMS; Tam TCC; Sim JPY; Tse EWC; Leung AYH; Kwong YL; Lie AKW; Ip MSM; Lam DCL
    Respirology; 2019 May; 24(5):459-466. PubMed ID: 30663178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Follow-Up of Ruxolitinib in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease.
    Ferreira AM; Szor RS; Molla VC; Seiwald MC; de Moraes PA; da Fonseca ARBM; Xavier EM; Serpa MG; Tucunduva L; Novis Y; Arrais-Rodrigues C
    Transplant Cell Ther; 2021 Sep; 27(9):777.e1-777.e6. PubMed ID: 34118469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of Screening Spirometry for Early Diagnosis of Bronchiolitis Obliterans Syndrome in Children After Allogeneic Hematopoietic Stem Cell Transplantation.
    Yoon JS; Chun YH; Lee JW; Chung NG; Cho B
    J Pediatr Hematol Oncol; 2015 Nov; 37(8):e462-7. PubMed ID: 26334431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
    Sengsayadeth SM; Srivastava S; Jagasia M; Savani BN
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1479-87. PubMed ID: 22449611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study.
    Yang W; Zhu G; Qin M; Li Z; Wang B; Yang J; Wang T
    Drug Des Devel Ther; 2021; 15():743-752. PubMed ID: 33654380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients.
    Gagliardi TA; Milner J; Cairo MS; Steinberg A
    Cureus; 2022 Sep; 14(9):e29195. PubMed ID: 36258935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease.
    Chien JW; Duncan S; Williams KM; Pavletic SZ
    Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S106-14. PubMed ID: 19896545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of lung function changes with outcomes in children with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
    Jung S; Yoon HM; Yoon J; Park M; Rhee ES; Kim H; Koh KN; Lee JS; Im HJ; Yu J
    Pediatr Pulmonol; 2021 Oct; 56(10):3332-3341. PubMed ID: 34357700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.